RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.03
+2.16%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 369.51x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -1.94x
- Price / sales
- 164.49x
- Price / cash flow
- -3.19x
Enterprise value
- Enterprise value
- $159.2M
- EV / sales
- 107.78x
- EV / EBITDA
- -1.01x
- EV / EBIT
- -1.61x
- Market cap
- $243.0M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026